StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

Research analysts at StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the stock. Separately, HC Wainwright dropped their target price on shares of Oncternal Therapeutics from $28.00 to $19.00 and set a […]

Related Keywords

,Oncternal Therapeutics Company Profile ,Securities Exchange Commission ,Nasdaq ,Oncternal Therapeutics Inc ,Pasadena Private Wealth ,Oncternal Therapeutics ,Get Free Report ,Director Robert James Wills ,Exchange Commission ,Private Wealth ,Free Report ,Orphan Receptor ,Oncternal Therapeutics Daily ,